Innoviva (INVA) Capital Expenditures (2010 - 2026)

Innoviva (INVA) posted Capital Expenditures of $492000.0 for Q1 2026, down 56.11% on a QoQ basis from $1.1 million in Q3 2025.

Innoviva (INVA) Capital Expenditures (2010 - 2026) Analysis & Trends

Innoviva's Capital Expenditures history runs 14 years deep, the most recent figure standing at $492000.0 for Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $492000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 597.41% YoY) and the FY2025 annual result came in at $1.1 million, up 318.89% from the prior year.
Capital Expenditures was $492000.0 for Q1 2026 at Innoviva, down from $1.1 million in the prior quarter.
Across five years, Capital Expenditures topped out at $1.1 million in Q3 2025 and bottomed at $9000.0 in Q1 2022.
A 5-year average of $278875.0 and a median of $146500.0 in 2022 frame the typical range for Capital Expenditures.
Annual changes were most pronounced in 2023 — Capital Expenditures soared 687.88% — and 2024, when it advanced 3.85%.
Innoviva's Capital Expenditures stood at $33000.0 in 2022, then surged by 687.88% to $260000.0 in 2023, then grew by 3.85% to $270000.0 in 2024, then surged by 315.19% to $1.1 million in 2025, then plunged by 56.11% to $492000.0 in 2026.
Business Quant data shows INVA's Capital Expenditures at $492000.0 in Q1 2026, $1.1 million in Q3 2025, and $270000.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Innoviva	1.57 Bn	969.11 Mn	75.83 Mn	492,000.00

Download Data